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Background: Protein S100B has proven to be a useful biomarker for cerebral damages.
Increased levels of serum and cerebrospinal fluid (CSF) S100B have been shown in patients
suffering subarachnoid hemorrhage (SAH), severe head injury and stroke. In patients with
SAH, the course of S100B levels has been correlated with neurological deficits and out-
come. Cerebral vasospasm is a major contributor to morbidity and mortality. The primary
aim of this study was to investigate the potential of S100B protein as a predictor of cerebral
vasospasm in patients with severe SAH.
Materials and Methods: Patients with SAH, Fisher grade 3 and 4, were included in the
study. Five samples of CSF and serum S100B were collected from each patient. The first
sample (baseline sample) was drawn within the first 3 days following ictus and the fol-
lowing four samples, once a day on days 5–8, with day of ictus defined as day 1. Clinical
suspicion of cerebral vasospasm confirmed by computed tomography angiography was
used to diagnose cerebral vasospasm.
Results: A total of 18 patients were included. Five patients (28%) developed cerebral
vasospasm, two (11%) developed ventriculitis. There were no significant differences
between S100B for those with and without vasospasm. Serum S100B levels in patients
with vasospasm were slightly lower within the first 5 days following ictus, compared to
patients without vasospasm. Two out of five patients had elevated and increasing serum
S100B prior to vasospasm. Only one showed a peak level of S100B 1 day before vasospasm
could be diagnosed. Due to the low number of patients in the study, statistical significance
could not be reached.
Conclusion: Neither serum nor CSF S100B can be used as predictor of cerebral vasospasm
in patients suffering from SAH.
Keywords: protein S100B, subarachnoid hemorrhage, cerebral vasospasm, CT angiography, cerebrospinal fluid,
serum
INTRODUCTION
Subarachnoid hemorrhage (SAH) accounts for approximately 6–
8% of all strokes, and the leading cause is rupture of intracere-
bral aneurysms in 85% of the cases. The remaining causes are
due to arteriovenous malformation (AVM) bleeding, vertebral
artery dissection (about 5% together), or due to more unde-
fined causes or the perimesencephalic SAH, which account for
about 10% of the cases (van Gijn and Rinkel, 2001). The over-
all incidence of SAH is approximately 9 per 100,000 persons/year,
slightly higher in the Scandinavian countries, an highest in Fin-
land and Japan with 19.7 and 22.7 per 100,000/year, respectively
(de Rooij et al., 2007). Mortality and morbidity is high, account-
ing for up to 50% in patients suffering from aneurysmal SAH
(aSAH). About 25% never reach medical attention (Diringer,
2009).
Cerebral vasospasm is an important cause of morbidity and
death after SAH (Rowland et al., 2012), for those who survive
to receive medical treatment. It is defined as clinical neurological
symptoms of ischemia (confusion, decreased level of conscious-
ness, focal neurological deficits), with narrowing of cerebral ves-
sels, visualized by computed tomography angiography (CTA).
Cerebral vasospasm occur in approximately one third of aSAH
patients (Frontera et al., 2009), and the risk of vasospasm is related
to the thickness and amount of blood in the subarachnoid space
and/or the presence of intraventricular blood assessed on com-
puted tomography (CT), the Fisher grade (Fisher et al., 1980; Jung
et al., 2012). The risk of developing cerebral vasospasm is highest
during dag 6–8 following ictus (Weir et al., 1978). SAH patients are
clinically monitored with daily neurological examinations, but the
means of diagnosing cerebral vasospasm varies. The techniques in
use for diagnosing vasospasm are by means of clinical evaluation,
transcranial doppler sonography (TCD), CTA, digital subtraction
angiography (DSA), or by computed tomography perfusion (CTP)
(Yoon et al., 2006; Washington and Zipfel, 2011; Kunze et al., 2012),
although the most relevant technique is still not defined (Frontera
et al., 2009).
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A biomarker for detection of cerebral vasospasm in patients
with SAH, could ideally allow for early detection to prevent delayed
ischemic neurological deficits. Protein S100B is a calcium binding
protein, predominant in nervous tissue, and mainly expressed in
astroglial cells (Donato, 2001). It is also found in extracerebral
tissues, such as long bones, fat, melanocytes, heart, and kidneys,
though in lesser extent (Anderson et al., 2001; Unden et al., 2005).
S100B is increased in serum and in cerebrospinal fluid (CSF) after
brain injury, mainly as a result of the opening of the blood brain
barrier (Marchi et al., 2003). In recent years, studies have shown
that S100B is useful as a predictive marker for outcome after cere-
bral infarction (Herrmann and Ehrenreich, 2003; Ahmad et al.,
2012), anoxic brain injury (Shinozaki et al., 2009), and SAH (Wies-
mann et al., 1997; Stranjalis et al., 2007; Sanchez-Pena et al., 2008).
The aim of our study was to investigate the potential of S100B




We prospectively studied patients with SAH, admitted to Copen-
hagen University Hospital, neurointensive care unit (NICU)
between September 2012 and January 2013. The inclusion cri-
teria were: patients with SAH confirmed by CT, Fisher grade 3
and 4, age 18 years and above, admission and external ventricu-
lar drain (EVD) within 3 days of ictus, no other major injuries.
Patients who had their EVD removed within the first 8 days after
ictus were excluded from the study.
Glasgow Coma Scale (GCS) score (Teasdale and Jennett, 1974)
and WFNS grading scale (Teasdale et al., 1988) was used to assess
the neurological status on admission. Location and thickness of
the hemorrhage on CT scan was determined by the Fisher grading
scale (Fisher et al., 1980).
SAMPLES
A total of five blood samples and five CSF samples were obtained
from each patient. The day of ictus was defined as day 1. The first
blood and CSF samples (Baseline sample) were obtained between
day 1 and 3, depending on when the patient was transferred to the
NICU and had received an EVD. The following four samples were
obtained on day 5–8 following ictus. Each blood sample consisted
of 4 ml of blood obtained in a SST-tube with separating gel with-
out additives, and the CSF samples consisted of minimum 1 ml
of CSF obtained from the EVD. About 4 ml of blood and 1 ml
of CSF was taken as waste prior to sampling, as a precaution to
contamination and dilution effect. Following collection all sam-
ples were centrifuged at 3500 rpm for 7 min at room temperature.
The separated serum and CSF samples were stored at−80 °C, and
thawed prior to analysis. Samples were analyzed with the method
of electrochemiluminescence immunoassay, and the equipment
used was Elecsys 2010, Modular Analytics E170, Roche Diagnos-
tics (Mannheim, Germany). The lower detection limit was 0.005
and the upper limit 39µg/L.
VASOSPASM
Daily neurological status was assessed to determine clinical signs of
worsening with cerebral vasospasm as the primary cause. Cerebral
vasospasm was confirmed by CTA.
STATISTICS
Statistical analysis was performed in IBM SPSS Statistics ver.
19.0.0. Figures and tables were computed in Microsoft Excel
2007. Student t -test was performed for comparing mean S100B
levels between patients with and without cerebral vasospasm.
Significance level was set to 0.05.
ETHICAL CONSIDERATIONS
The study and the collection of S100B in both serum and CSF had
been approved by the local ethics committee.
RESULTS
A total of 18 patients with severe SAH were included, 16 had an
aSAH, one had SAH due to a small AVM bleeding, and one due
to dissection of the vertebral artery. Mean age was 60 years (range
42–84 years), there were 11 females and 7 males. The mean GCS
score on admission was 8, the mean score of the WFNS grad-
ing scale was 3.5, and the mean Fisher grade was 3.6. Patients
with aSAH were treated with endovascular coiling (81%) or sur-
gical clipping (19%). The two patients without aSAH were treated
conservatively.
The baseline samples were obtained on day 1 from one patient,
on day 2 from four patients and on day 3 from 13 patients. Five
patients developed cerebral vasospasm during the first week. None
developed cerebral vasospasm later than on day 8. Three patients
died, of which one developed cerebral vasospasm during the trial
period. Two patients developed bacterial ventriculitis during the
trial period.
When comparing patients who developed cerebral vasospasm
with those who did not, there were no significant differences in
GCS score at admission, Fisher grade or WFNS grade. Mean age
was slightly, but not significantly, higher in patients that developed
cerebral vasospasm (Table 1). The mean serum S100B level in
Table 1 | Characteristics of patients with cerebral vasospasm







Gender (M:F) 2:3 5:8
Mean age (years) 67 58
Mean GCS at admission 8 9
Mean WFNS grading score at admission 3.6 3.5
Mean Fisher grading score 3.6 3.5
Mean body temperature ( °C) 38.0 38.0




Day 1 1 0
Day 2 1 3
Day 3 3 10
Days 5–8 5 13
GCS, glasgow coma scale; WFNS, World federation of neurological societies
grading scale.
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patients who developed cerebral vasospasm compared to those
who did not, was lower within the first 5 days after ictus. Following
day 5, serum S100B levels in the group with cerebral vasospasm,
was increased and exceeded the mean level of serum S100B in
patients who did not developed vasospasm, though not statistically
significant (Table 2). The mean CSF S100B levels in patients who
developed cerebral vasospasm were lower compared to patients
without vasospasm, but not statistically significant. The peak and
mean body temperatures were generally high, but did not differ
between those who developed vasospasm and those who did not.
Among the five patients who developed cerebral vasospasm,
baseline samples of serum and CSF S100B were drawn on day
1 in one patient, at day 2 in one patient, and at day 3 in three.
Two patients had increasing levels of serum S100B compared to
the other three, which had an overall decreasing tendency and
normal levels of serum S100B when vasospasm was diagnosed.
Only one patient reached a peak level of serum S100B the day
before vasospasm was confirmed (Figure 1, patient B), while the
other patient reached peak S100B 1 day after angiographic con-
firmation of cerebral vasospasm and ongoing cerebral infarction
(Figure 1, patient E). Both patients had a WFNS score of 5 and a
GCS of 3 at admission, and both developed pneumonia during the
trial period. The other three patients with cerebral vasospasm had
slightly lower WFNS and slightly higher GCS scores at admission,
and none had pneumonia or other infections diagnosed during
the trial period.
Among patients who did not developed cerebral vasospasm,
the baseline samples were drawn on day 2 in three patients and on
day 3 in 13 patients. Two developed bacterial ventriculitis, with a
sudden 10-fold increase in serum S100B levels. One reached peak
level of serum S100B the day before developing ventriculitis, while
peak levels for the other patient occurred on the same day as the
Table 2 | Mean serum and CSF S100B levels in patients with cerebral vasospasm compared to patients without*.









Baseline 0.10 0.19 23.5 29.6
Day 5 0.15 0.37 13.8 21.8
Day 6 0.21 0.15 10.1 16.3
Day 7 0.27 0.11 12.7 15.7
Day 8 0.24 0.25 12.0 12.3
*There are no statistical differences between the two groups (vasospasm vs. no vasospasm).
FIGURE 1 | Serum S100B levels for the five patients with cerebral vasospasm. Day 1=day of ictus. Baseline sampling was made between day 1 and 3. The
dotted lines are extrapolations from baseline sample to the second sample drawn on day 5. The day on which cerebral vasospasm was confirmed is indicated
for each patient.
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infection was diagnosed. No such relation was observed for CSF
S100B.
DISCUSSION
We studied a total of 18 SAH patients by measuring S100B in
serum and CSF within the first 8 days following ictus. Five patients
developed cerebral vasospasm, detected by neurological deterio-
ration and confirmed with CTA. No significant differences for
S100B levels were observed when comparing patients who devel-
oped cerebral vasospasm to patients who did not, and S100B failed
predict the development of cerebral vasospasm.
Only two patients with cerebral vasospasm developed increased
levels of serum S100B during the trial period. Both patients were
in worse neurological condition (GCS 3, WFNS 5 at admission)
compared to the other patients who developed cerebral vasospasm
(Stranjalis et al., 2007). In addition, these two patients developed
pneumonia during the trial period. Two patients in the group
without cerebral vasospasm developed ventriculitis. High levels
of serum S100B were found on the day before or on the same
day as the clinical diagnosis of bacterial ventriculitis was set. The
results indicate an association between increased serum S100B and
intracerebral infections as shown in a previous study (Unden et al.,
2004).
Measurements of S100B in our patients were done once daily
with baseline sample obtained within the first 3 days of ictus and
the rest of the four samples on days 5–8 following ictus. The
baseline samples were obtained within the first 3 days of ictus,
as cerebral vasospasm usually do not occur before day 4 follow-
ing ictus. As the highest risk for developing vasospasm is between
6 and 8 days following the subarachnoid bleeding (Weir et al.,
1978), the subsequent samples were drawn on day 5–8. None of
the patients developed either clinical or angiographic vasospasm
after day 8.
In two patients the bleeding source was not an aneurysm, but a
small deep AVM in one patient, and a vertebral artery dissection in
the other. The risk of developing cerebral vasospasm increases with
increasing volume of subarachnoid blood visualized by CT (Fisher
et al., 1980; Adams et al., 1987). Both of these patients had high
amount of subarachnoid blood visualized on CT (Fisher grade 3
and 4), and thus high risk of developing cerebral vasospasm.
Currently, neurosurgical centers use daily assessment of neu-
rological status, TCD sonography and CTA to determine the
development of cerebral vasospasm. Most patients suffering from
severe SAH, have already, prior to transport to the NICU, been
sedated and intubated, making the assessment of the neurological
status in these patients challenging. In our study, clinical suspicion
of vasospasm in addition with CTA, rather than TCD, was used
to diagnose cerebral vasospasm. CTA has been found to correlate
well (overall agreement of 95%) with DSA (Yoon et al., 2006),
which has been considered as the gold standard in detecting cere-
bral vasospasm. Furthermore, Kunze et al. (2012) have shown that
the accuracy of neurological examination and CTP is higher in
detecting cerebral vasospasm than TCD, and in a systematic review
by Lysakowski and colleagues, they concluded that although TCD
has a high specificity (0.99) and positive predictive value (0.97)
for detecting vasospasm, this accounts only for the middle cere-
bral artery. For all the other arteries, there is no evidence for the
usefulness of TCD as a diagnostic tool for vasospasm (Lysakowski
et al., 2001).
Our study also show a tendency toward lower serum S100B
levels during the first 5 days following SAH in patients who devel-
oped cerebral vasospasm compared to those who did not. These
results were not statistically significant, thus not supporting use-
ful value of serum S100B in predicting vasospasm. Similar results
have been found by Oertel et al. (2006) who showed lower levels
of serum S100B within the first 3 days after SAH in patients who
developed cerebral vasospasm compared to those who did not.
Cerebral vasospasm was determined by neurological deterioration
and increasing flow velocity on TCD.
Identifying a specific biomarker for prediction of cerebral
vasospasm in this group of patients is of high value, since ear-
lier detection and hence earlier treatment of vasospasm could
lower the morbidity and mortality in this group of patients. The
statistical analysis of our end results are limited by the small
number of cases enrolled in the study. We can, however, con-
clude that, although S100B is a promising prognostic biomarker
of secondary brain damage and outcome in patients with SAH
(Stranjalis et al., 2007; Sanchez-Pena et al., 2008), the potential
of S100B as a predictor of cerebral vasospasm is very limited.
This is in accordance with two previous studies (Moritz et al.,
2010; Jung et al., 2013). The need of a marker in predicting
cerebral vasospasm still remains, and other biomarkers such as
myeloperoxidase (Lim et al., 2012), amino acids in addition to
microdialysis (Jung et al., 2013), endothelin-1, interleukin-6, and
indicators of thrombin activity might be of greater utility (Lad
et al., 2012).
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